You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
18 September 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) and its US partner Ollin Biosciences on Thursday announced a clinical update on IBI324 (Ollin R&D code: OLN324).IBI324 (OLN324) is a higher potency, higher ...
17 September 2025 - South Korean biopharmaceutical company Alteogen Inc. (KOSDAQ:196170) announced on Wednesday that the European Commission has granted marketing authorisation for EYLUXVI (ALT-L9), an Eylea (aflibercept) biosimilar co-developed with...
17 September 2025 - Medicine firm Eli Lilly and Company (NYSE: LLY) on Wednesday reported positive topline results from ACHIEVE-3, a Phase 3, 52-week trial comparing the oral GLP-1 receptor agonist orforglipron to oral semaglutide in 1,698 adults wit...
Biocon Biologics wins U.S. FDA approval for interchangeable denosumab biosimilars Bosaya and Aukelso
17 September 2025 - Biosimilars company Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE: 532523) (NSE: BIOCON), announced on Wednesday that it has secured U.S. Food and Drug Administration (FDA) approval for Bosaya and Aukelso, biosimilar...
17 September 2025 - Biopharmaceutical company AstraZeneca plc (LSE: AZN) (STO: AZN) (Nasdaq: AZN) reported on Wednesday that its Phase III RESOLUTE trial of Fasenra (benralizumab) in chronic obstructive pulmonary disease (COPD) did not achieve statis...
17 September 2025 - Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) confirmed on Wednesday that the third patient in its Phase I clinical trial of HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukaemia (AML) has succe...
17 September 2025 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) said on Wednesday that it has agreed a partnership with Chinese biopharmaceutical company Changchun GeneScience Pharmaceutical (GenSci) to commercialise its hou...